Clinical trials
High Risk Acute Myeloid Leukemia clinical trials
Below are recruiting high risk acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05986240RecruitingPhase 1
Danvatirsen with or without venetoclax for advanced MDS or AML
This trial tests a new drug called danvatirsen, first alone and then combined with venetoclax, for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this approach can help when other options have stopped working.
The Bronx, New YorkAges 18 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT06424340RecruitingPhase 1/Phase 2
Cell therapy for relapsed or refractory AML with NPM1 mutation
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
LeidenAges 18 years+ - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06571825RecruitingPhase 4
Comparing transplant vs. venetoclax for older adults with AML
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
Hangzhou, ZhejiangAges 60–75 - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06714591RecruitingPhase 1
Testing BL-M11D1 for advanced AML
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Duarte, CaliforniaAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06928376RecruitingPhase 2
Venetoclax plus chemo vs standard chemo for AML
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 14–75 - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07321626RecruitingPhase 1
Romiplostim for platelet recovery after stem cell transplant
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
HangzhouAges 18 years+ - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT01210274Recruiting
Study how people resist azacitidine in blood cancers
This study looks at why some people with higher-risk blood cancers (MDS/AML-MD) do not respond as well to azacitidine. The goal is to learn the causes of resistance so future treatments may work better.
AntibesAges 18 years+ - NCT07583888RecruitingPhase 2/Phase 3
VABu Conditioning for Older Adults with Acute Myeloid Leukemia
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
Suzhou, JiangsuAges 60 years+ - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT07607418RecruitingPhase 2
Ivosidenib maintenance therapy for IDH1-mutated blood cancers
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07613385Recruiting
Personalized Treatment Plan for Relapsed or Resistant AML
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk acute myeloid leukemia?
- Yes. Clin2 currently lists 207 recruiting high risk acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.